Scholarlink

Background <p><i>Aeromonas dhakensis</i> is an emerging and potentially more virulent species within the <i>Aeromonas</i> genus, frequently misidentified in routine laboratories, leading to underrecognition and suboptimal management.</p> Objectives <p>To describe the clinical spectrum, laboratory characteristics, and antimicrobial susceptibility patterns of <i>A. dhakensis</i> isolated from clinically significant specimens in a tertiary-care setting.</p> Methods <p>A retrospective case series was conducted at a tertiary-care teaching hospital during November–December 2025. Clinical and microbiological records of patients with <i>A. dhakensis</i> isolated from clinically relevant specimens were reviewed. Species identification was performed using MALDI-TOF MS with updated databases, and antimicrobial susceptibility testing was interpreted according to CLSI guidelines.</p> Results <p>Four cases of clinically significant <i>A. dhakensis</i> infection were identified (median age 43 years), involving pleural fluid, pus aspirate, endotracheal aspirate, and urine. Clinical presentations included hydropneumothorax, breast abscess, neurosurgical complications, and urinary tract infection. Two patients required ICU care and mechanical ventilation. Laboratory findings showed mild anemia and leukocytosis in select cases. All isolates demonstrated uniform resistance to carbapenems and piperacillin–tazobactam, while retaining susceptibility to fluoroquinolones, aminoglycosides, third- and fourth-generation cephalosporins, aztreonam, trimethoprim–sulfamethoxazole, and doxycycline. All patients improved with appropriate therapy and survived to discharge.</p> Conclusion <p><i>A. dhakensis</i> is an emerging invasive pathogen with a characteristic resistance profile marked by intrinsic carbapenem resistance. Accurate species-level identification using MALDI-TOF MS and susceptibility-guided therapy are essential. This study provides region-specific evidence highlighting the need for increased clinical awareness, diagnostic stewardship, and surveillance.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Aeromonas dhakensis as an emerging invasive pathogen: a case series highlighting distinct carbapenem resistance and diagnostic challenge

  • 期刊论文

  • 发表日期：

    2026年6月25日

查看全文
  • Sheetal Verma,
  • Kalpana Kuntal,
  • Harsh Deep,
  • Vimala Venkatesh,
  • Somil Jaiswal,
  • Anand Kumar Mishra

摘要

Background

Aeromonas dhakensis is an emerging and potentially more virulent species within the Aeromonas genus, frequently misidentified in routine laboratories, leading to underrecognition and suboptimal management.

Objectives

To describe the clinical spectrum, laboratory characteristics, and antimicrobial susceptibility patterns of A. dhakensis isolated from clinically significant specimens in a tertiary-care setting.

Methods

A retrospective case series was conducted at a tertiary-care teaching hospital during November–December 2025. Clinical and microbiological records of patients with A. dhakensis isolated from clinically relevant specimens were reviewed. Species identification was performed using MALDI-TOF MS with updated databases, and antimicrobial susceptibility testing was interpreted according to CLSI guidelines.

Results

Four cases of clinically significant A. dhakensis infection were identified (median age 43 years), involving pleural fluid, pus aspirate, endotracheal aspirate, and urine. Clinical presentations included hydropneumothorax, breast abscess, neurosurgical complications, and urinary tract infection. Two patients required ICU care and mechanical ventilation. Laboratory findings showed mild anemia and leukocytosis in select cases. All isolates demonstrated uniform resistance to carbapenems and piperacillin–tazobactam, while retaining susceptibility to fluoroquinolones, aminoglycosides, third- and fourth-generation cephalosporins, aztreonam, trimethoprim–sulfamethoxazole, and doxycycline. All patients improved with appropriate therapy and survived to discharge.

Conclusion

A. dhakensis is an emerging invasive pathogen with a characteristic resistance profile marked by intrinsic carbapenem resistance. Accurate species-level identification using MALDI-TOF MS and susceptibility-guided therapy are essential. This study provides region-specific evidence highlighting the need for increased clinical awareness, diagnostic stewardship, and surveillance.